An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This research study involves the use of two investigational drugs: sorafenib and bortezomib.
Sorafenib is designed to stop the growth of cells caused by changes associated with cancer.
Bortezomib is designed to stop cancer cells from getting rid of waste products. This causes
the cells to build up toxic levels of waste that leads to cell death. In the laboratory, the
combination of sorafenib and bortezomib has been shown to fight cancer cells better than
either drug alone. We are looking to determine if the combination of sorafenib and bortezomib
is a safe treatment for patients with advanced melanoma. The effectiveness of this
combination will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Bayer Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Millennium Pharmaceuticals, Inc.